These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 23286538)

  • 1. [Use of intravenous humana immunoglobulin in rheumatic diseases].
    Mussano ED; Onetti LB; Cadile II; Onetti CM
    Rev Fac Cien Med Univ Nac Cordoba; 2012; 69(2):90-6. PubMed ID: 23286538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.
    Lidar M; Masarwa S; Rotman P; Carmi O; Rabinowicz N; Levy Y
    Immunol Res; 2018 Dec; 66(6):668-674. PubMed ID: 30565202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin therapy in rheumatic diseases.
    Bayry J; Negi VS; Kaveri SV
    Nat Rev Rheumatol; 2011 Jun; 7(6):349-59. PubMed ID: 21556030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin therapy: magic or black magic.
    Barron KS; Sher MR; Silverman ED
    J Rheumatol Suppl; 1992 Apr; 33():94-7. PubMed ID: 1593608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis.
    Moretti M; Buiatti A; Merlo M; Massa L; Fabris E; Pinamonti B; Sinagra G
    Am J Cardiol; 2013 Nov; 112(9):1493-8. PubMed ID: 23972350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus].
    Francioni C; Fioravanti A; Gelli R; Megale F; Marcolongo R
    Recenti Prog Med; 1993 Oct; 84(10):679-86. PubMed ID: 8235034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of intravenous immunoglobulin in the treatment of rheumatic diseases in adults].
    Swierkot J; Lewandowicz-Uszyńska A
    Pol Merkur Lekarski; 2011 Jun; 30(180):435-40. PubMed ID: 21751555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases.
    Zandman-Goddard G; Krauthammer A; Levy Y; Langevitz P; Shoenfeld Y
    Clin Rev Allergy Immunol; 2012 Apr; 42(2):247-55. PubMed ID: 21732045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
    Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
    Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE).
    Goodfield M; Davison K; Bowden K
    J Dermatolog Treat; 2004 Jan; 15(1):46-50. PubMed ID: 14754650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin therapy for rheumatic diseases.
    Sany J
    Curr Opin Rheumatol; 1994 May; 6(3):305-10. PubMed ID: 8060767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience.
    De Vita S; Ferraccioli GF; Di Poi E; Bartoli E; Bombardieri S
    Clin Exp Rheumatol; 1996; 14 Suppl 15():S85-92. PubMed ID: 8828953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus.
    Toubi E; Kessel A; Shoenfeld Y
    Hum Immunol; 2005 Apr; 66(4):395-402. PubMed ID: 15866703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis.
    Liew WK; Powell CA; Sloan SR; Shamberger RC; Weldon CB; Darras BT; Kang PB
    JAMA Neurol; 2014 May; 71(5):575-80. PubMed ID: 24590389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intravenous immunoglobulin (IVIG)].
    Hara M
    Nihon Rinsho; 2009 Mar; 67(3):599-605. PubMed ID: 19280939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
    Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
    J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases.
    Sherer Y; Kuechler S; Jose Scali J; Rovensky J; Levy Y; Zandman-Goddard G; Shoenfeld Y
    Isr Med Assoc J; 2008 Jan; 10(1):55-7. PubMed ID: 18300575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients.
    Shoenfeld Y; Katz U
    Autoimmunity; 2005 Mar; 38(2):123-37. PubMed ID: 16040333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases.
    Salonen EM; Miettinen A; Walle TK; Koskenmies S; Kere J; Julkunen H
    Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.